Fig. 4

Novel BenSer targets are expressed in breast cancer. a, [³H]-substrate uptake was assessed in oocytes expressing LAT2/SLC7A8 and heavy chain SLC3A2, ASCT1/SLC1A4, ASCT2/SLC1A5, SNAT1/SLC38A1, or SNAT2/SLC38A2 in the presence or absence of 10 mM BenSer. Data from one representative batch of oocytes are presented. Each datapoint represents the mean ± SEM values (n ≥ 4) for the difference between the mean uptake by ‘n’ injected oocytes and the mean uptake by ‘n’ uninjected oocytes. The variance of this difference was calculated using Gauss’ law of error propagation. Data were normalised to the control condition (uptake in the absence of BenSer). b, gene expression (mRNA log₂ values) of LAT transporters (SLC7A5, SLC7A8, SLC43A1, SLC43A2), LAT common heavy chain (SLC3A2) and glutamine transporters (SNATs: SLC38A1, SLC38A2; ASCT2/SLC1A5, ASCT1/SLC1A4) was analysed in all breast cancer cell lines (n = 55) included in The Cancer Cell Line Encyclopedia (TCCLE). Grouped data are plotted as box-and-whisker plots (max to min), with log₂ mRNA expression in MCF-7 (red), HCC1806 (blue) and MDA-MB-231 (MDA-231; green) cells overlaid as individual data points. c-h, mRNA expression (log₂ values) of SLC7A5 (c), SLC7A8 (d), SLC1A5 (e), SLC1A4 (f) SLC38A1 (g), and SLC38A2 (h) in the METABRIC dataset (n = 2509). Data were grouped into the “PAM50 + Claudin-low” subtypes based on clinical attribute data retrieved from www.cbioportal.org/ and are plotted as box-and-whisker plots (Tukey)